Recent data suggests that we may be turning a corner in the quest for a disease modifying drug for Alzheimer's Disease ("AD"}. With Lilly's Phase 2 posive donanemab data supporng its mode of acon ("MoA"), VVY's varoglutamstat (PQ912) is on crest of the new AD therapy wave. With signs of efficacy from SAPHIR Phase 2a, the drug is well-placed to become one of the first AD modifying drugs. Orally delivered with acceptable tolerability, it should also be well suited to combinaon therapy that wil ....
17 May 2021
Varoglutamstat on crest of Alzheimer therapy wave
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Varoglutamstat on crest of Alzheimer therapy wave
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
17 May 2021 -
Author:
Chris Redhead -
Pages:
28
Recent data suggests that we may be turning a corner in the quest for a disease modifying drug for Alzheimer's Disease ("AD"}. With Lilly's Phase 2 posive donanemab data supporng its mode of acon ("MoA"), VVY's varoglutamstat (PQ912) is on crest of the new AD therapy wave. With signs of efficacy from SAPHIR Phase 2a, the drug is well-placed to become one of the first AD modifying drugs. Orally delivered with acceptable tolerability, it should also be well suited to combinaon therapy that wil ....